Search the Newsreel

Compass Pathways to Announce Second Quarter and First Half 2026 Financial Results on August 5, 2026

Compass Pathways plc (Nasdaq: CMPS) will release its financial results for the second quarter and first half ended June 30, 2026, on August 5, 2026. The company's management will host a conference call on the same day at 8:00 am ET (1:00 pm UK) …

Compass Pathways: The Psilocybin Biotech Leader With Strong Momentum (NASDAQ:CMPS)

Compass Pathways (CMPS) is positioned as a leader in regulated psilocybin therapy, with two successful Phase 3 trials and a rolling FDA submission for COMP360 targeting treatment-resistant depression. The company benefits from a substantial unmet need in depression, with additional long-term potential in PTSD …

Orbimed Advisors LLC Buys New Shares in Compass Pathways PLC Sponsored ADR $CMPS

Compass Pathways PLC (CMPS) Valuation: PE, PB & Fair Value Analysis

This article provides a brief overview of Compass Pathways PLC (CMPS) stock data, including its market cap, recent price, and performance. It notes that key valuation metrics like P/E, P/B, and P/CF ratios have not been disclosed by the company. The page appears to …

Compass Pathways PLC (CMPS) Earnings Date & Reports & Earnings News

Compass Pathways PLC (CMPS) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Compass Pathways PLC (CMPS), including analyst ratings, price targets, and past and projected earnings per share (EPS). Based on 17 analysts, the stock has a "Buy" trend with a target price of USD 23.441, representing a potential …

CMPS|Compass Pathways PLC|Price:11.260|Chg%:-0.450

This article provides a detailed financial overview of Compass Pathways PLC (CMPS), including its stock performance, key financial figures, analyst ratings, and company information. CMPS is a biotechnology company focused on mental health, specifically developing its COMP360 psilocybin treatment for conditions like treatment-resistant depression. …

Could COMPASS Pathways’ (CMPS) Low-Touch Psilocybin Protocol Quietly Redefine Its Competitive Edge in PTSD?

COMPASS Pathways (CMPS) recently released a post-hoc analysis of its COMP360 psilocybin treatment for PTSD, highlighting a low-intervention, standardized support model. This approach, characterized by minimal and largely non-directive support during administration sessions, could enhance the scalability and consistency of COMP360 across various conditions. …

Compass Pathways (CMPS) to Post Quarterly Earnings on Thursday

CMPS stock trades steadily as Compass Pathways expands psilocybin depression program

Compass Pathways' CMPS stock is closely tied to its progress in developing psilocybin therapy for treatment-resistant depression, with investors monitoring trial milestones, cash reserves, and Nasdaq trading performance. The company, a clinical-stage biotech, has no commercial revenue but emphasizes its cash position and R&D …

Compass Pathways gains Jefferies support as COMP360 data distinguishes psychological support from psychotherapy

Jefferies analysts have expressed support for Compass Pathways' COMP360 treatment model, noting that a new Phase II analysis differentiates its psychological support from traditional psychotherapy. This distinction could lead to fewer regulatory hurdles, with Jefferies estimating a high confidence level for FDA approval of …

COMPASS Pathways (CMPS) Is Down 8.6% After Phase 3 Durability Data For COMP360 In TRD

COMPASS Pathways (CMPS) saw its stock drop by 8.6% following the release of 26-week data from its Phase 3 COMP006 trial for COMP360 psilocybin in treatment-resistant depression (TRD). While the data showed rapid onset, durable clinical benefit, and a manageable safety profile, reinforcing the …

Should COMP360’s Durable Phase 3 Results and FDA Momentum Require Action From COMPASS Pathways (CMPS) Investors?

COMPASS Pathways (CMPS) recently reported positive 26-week Phase 3 data for its COMP360 psilocybin candidate, showing rapid, durable symptom improvement for treatment-resistant depression with a well-tolerated safety profile. These results, coupled with an ongoing rolling New Drug Application and a more favorable FDA stance …

Does COMPASS Pathways (CMPS) Have Upside Left Above Fair Value?

Is COMPASS Pathways plc (CMPS) A Good Stock To Buy Now?

Is COMPASS Pathways (CMPS) Quietly Recalibrating Its Commercialization Strategy With This Board Appointment?

Compass Pathways stock maintained at Buy by TD Cowen on NDA progress

Compass (CMPS) Q1 2026 Earnings Transcript

Compass Pathways jumps after earnings beat and accelerated FDA review progress (CMPS)

Compass Pathways pairs Q1 results with a business update on May 13

Why COMPASS Pathways (CMPS) Is Up 15.4% After Psilocybin Phase 3 Wins And FDA Filing Momentum

Biotech Compass Pathways secures $200M for PTSD, Phase 3 trials

COMPASS Pathways plc's (NASDAQ:CMPS) institutional investors lost 16% over the past week but have profited from longer-term gains